ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Clinical and molecular determinants of response to maintenance olaparib for primary and recurrent epithelial ovarian carcinoma.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Context-dependent roles of HtrA2/Omi in ovarian cancer: mitochondrial apoptotic function linking platinum sensitivity and acquired chemoresistance-a narrative review.Translational cancer research · 2026Review
- Receptor Co‑targeting Strategies for Personalized Ovarian Cancer Therapy.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo characterize long-term (LT) and short-term (ST) responders to the Poly (ADP-ribose) polymerase inhibitor olaparib in the primary and recurrent maintenance setting.
methodsClinical and molecular data was collected for patients receiving maintenance olaparib between January 2014 and July 2021. ST responders were defined as those experiencing progression < 6 months from initiating olaparib, whereas LT responders exhibited response ≥ 2 years. Molecular analysis included germline BRCA1/2 status, Myriad MyChoice CDx Homologous Recombination Deficiency (HRD) somatic testing, and STRATA Select comprehensive genomic profiling.
results124 patients who received olaparib were included; 45 (36.3%) LT and 31 (25.0%) ST responders were identified. BRCA2 mutations were enriched among the LT responders compared to ST responders (16 (35.5%) v. 4 (12.9%), p = 0.028) and LT responders were more likely to be HRD (40 (88.9%) v 19 (61.3%), p = 0.005). Patients receiving olaparib following platinum-sensitive recurrence were more likely to experience ST response compared to the primary setting (24 (55.8%) vs 7 (21.2%), p = 0.002). In both the primary and recurrent setting, LT responders were more likely to have a complete response to the most recent chemotherapy when compared to those experiencing ST response (24 (92.3%) v. 3 (42.9%), for primary maintenance, p = 0.021 and 10 (52.6%) v. 3 (12.5%) for recurrent, p = 0.004).
conclusionsLT response to olaparib for primary maintenance is common, and more frequently observed in patients with a complete response to platinum-based chemotherapy. BRCA2 mutations conferred exceptional benefit to olaparib. Durable benefit was more commonly observed in patient's receiving frontline maintenance olaparib.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.